Martin Hoyle

Professor

  • 1236 Citations
  • 21 h-Index
20042022
If you made any changes in Pure these will be visible here soon.

Research Outputs 2004 2019

  • 1236 Citations
  • 21 h-Index
  • 47 Article
  • 19 Commissioned report
  • 1 Other report
  • 1 Review article
Filter
Commissioned report
2019

Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis

Tikhonova, I., Yang, H., Salmon, A., Bello, S., Peters, J., Robinson, S., Rezaei, M., Dodman, S., Coelho, H., Kharechko, A., Haigh, R., Jani, M., McDonald, T. J., Hoyle, M. & Logan, S., 2019, University of Exeter. 425 p.

Research output: Book/ReportCommissioned reportResearch

Open Access
2018

Benralizumab for treating severe asthma: A Single Technology Appraisal

Tikhonova, I., Long, L., Ocean, N., Barnish, M., Robinson, S., Nikram, E., Bello, S., Dodman, S., Halpin, D. & Hoyle, M., 2018, University of Exeter. 223 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib [ID1328]: A Single Technology Appraisal

Griffin, E., Barnish, M., Packman, D., Coelho, H., Matthews, J., Dodman, S., Robinson, S., Dangoor, A., Dorey, N. & Hoyle, M., 2018, University of Exeter. 189 p.

Research output: Book/ReportCommissioned reportResearch

Open Access
2017

Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma: A Single Technology Appraisal

Tikhonova, I., Jones-Hughes, T., Dunham, J., Warren, F., Robinson, S., Stephens, P. & Hoyle, M., 2017, University of Exeter. 167 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours: A Single Technology Appraisal

Jones-Hughes, T., Dunham, J., Robinson, S., Napier, M. & Hoyle, M., 2017, University of Exeter. 142 p.

Research output: Book/ReportCommissioned reportResearch

Open Access
2016

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: A Single Technology Appraisal

Mujica Mota, R., Varley-Campbell, J., Tikhonova, I., Cooper, C., Hoyle, M., Rudin, C. & Snowsill, T., 2016, University of Exeter. 145 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression

Varley-Campbell, J., Mujica Mota, R., Tikhonova, I., Cooper, C., Griffin, E., Haasova, M., Peters, J., Lucherini, S., Talens-Bou, J., Long, L., Sherriff, D., Napier, M., Ramage, J. & Hoyle, M., 2016, University of Exeter. 372 p.

Research output: Book/ReportCommissioned reportResearch

Open Access
Lutetium
Neuroendocrine Tumors
Disease Progression
Cost-Benefit Analysis
Quality-Adjusted Life Years
2015

Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer [ID794]: Multiple Technology Appraisal (MTA)

Huxley, N., Crathorne, L., Varley-Campbell, J., Tikhonova, I., Snowsill, T., Briscoe, S., Peters, J., Bond, M., Napier, M. & Hoyle, M., 2015, University of Exeter. 24 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85): A systematic review and economic model

Jones-Hughes, T., Snowsill, T., Haasova, M., Coelho, H., Crathorne, L., Cooper, C., Mujica-Mota, R., Peters, J., Varley-Campbell, J., Huxley, N., Moore, J., Allwood, M., Lowe, J., Hyde, C., Hoyle, M., Bond, M. & Anderson, R., 2015, University of Exeter. 759 p.

Research output: Book/ReportCommissioned reportResearch

Open Access
2014

Obinutuzumab in combination with chlorambucil for previously untreated chronic lymphocytic leukaemia: a critique of the submission from Roche

Hoyle, M., Long, L., Huxley, N., Crathorne, L., Briscoe, S. & Rudin, C., 2014, University of Exeter. 190 p.

Research output: Book/ReportCommissioned reportResearch

Open Access
2013

Bosutinib for previously treated chronic myeloid leukaemia: a single technology appraisal

Hoyle, M., Snowsill, T., Haasova, M., Cooper, C. & Rudin, C., 2013, University of Exeter. 304 p.

Research output: Book/ReportCommissioned reportResearch

Open Access
2011

Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses

Hoyle, M., Pavey, T., Ciani, O., Crathorne, L., Jones-Hughes, T., Cooper, C., Osipenko, L., Venkatachalam, M., Rudin, C., Ukoumunne, O., Garside, R. & Anderson, R., 2011, University of Exeter. 242 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of TA111): a systematic review and economic model

Bond, M., Rogers, G., Peters, J., Anderson, R., Hoyle, M., Miners, A., Moxham, T., Davis, S., Thokala, P., Wailoo, A., Jeffreys, M. & Hyde, C., 2010, University of Exeter. 403 p.

Research output: Book/ReportCommissioned reportResearch

Open Access
2009

The clinical and cost-effectiveness of sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer

Bond, M., Hoyle, M., Moxham, T., Napier, M. & Anderson, R., 2009, University of Exeter. 101 p.

Research output: Book/ReportCommissioned reportResearch

Open Access
2008

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Thompson-Coon, J., Hoyle, M., Green, C., Liu, Z., Welch, K., Moxham, T. & Stein, K., 2008, University of Exeter. 307 p.

Research output: Book/ReportCommissioned reportResearch

Open Access
Open Access